Foamix's minocycline foam meets in third Phase III for acne

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) reported on Sept. 11 that FMX101 met the co-primary endpoints in the Phase III FX2017-22 trial to treat moderate to severe acne. By year end,

Read the full 295 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE